Federal Register / Vol. 62, No. 224 / Thursday, November 20, 1997 / Notices 62061

sample of Gulf War veterans

participating in the Department of

Veterans Affairs Gulf War Registry; and

(2) a cohort of Air Force members from

a previous CDC study of Gulf War

veterans and Gulf War-era controls from

Pennsylvania and Florida. In addition to

assessing data-driven case definitions

for illness among Gulf War veterans,

existing definitions for medically

unexplained symptoms, such as chronic

fatigue syndrome, multiple chemical

sensitivity, and fibromyalgia will be

evaluated. Phase II will attempt to

assess the generalizability of both

derived and existing case definitions in

a random sample of deployed and nondeployed Gulf War era veterans. Phase

III will consist of a standardized

telephone interview for the assessment

of psychiatric conditions. This will be

administered to a sample of Phase I and

Phase II participants who are identified

through their responses to paper-andpencil questionnaires as having high

levels of psychologic distress. There is

no cost to respondents.

Respondents No. of

Respondents

No. of

Responses/

Respondent

Avg. Burden/

Response

(in hrs.)

Total Burden

(in hrs.)

Administer questionnaire to the New Jersey Center for Environmental Hazards Research sample of the Department of Veterans Affairs Gulf War

Registry veterans and the previous CDC Air Force Cohort (Phase) ........... 7,312 1 0.45 5,484

Administer questionnaire to new random sample of Gulf War veterans and

era controls (Phase II) .................................................................................. 3,000 1 .45 2,250

Telephone survey of Phase I and Phase II participants who screened positive for psychiatric conditions ........................................................................ 600 1 2 1,200

Total ........................................................................................................... ........................ ........................ ........................ 8,934

Dated: November 13, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning

and Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–30477 Filed 11–19–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Citizens Advisory Committee on Public

Health Service (PHS) Activities and

Research at Department of Energy

(DOE) Sites: Idaho National

Engineering and Environmental

Laboratory Health Effects

Subcommittee; Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Agency for Toxic

Substances and Disease Registry

(ATSDR) and the Centers for Disease

Control and Prevention (CDC) announce

the following meeting.

Name: Citizens Advisory Committee on

PHS Activities and Research at DOE Sites:

Idaho National Engineering and

Environmental Laboratory (INEEL) Health

Effects Subcommittee.

Times and Dates: 8:30 a.m.–5 p.m.,

December 11, 1997, 7 p.m.–9 p.m., December

11, 1997, 8:30 a.m.–4 p.m., December 12,

1997.

Place: Holiday Inn Westbank, 475 River

Parkway, Idaho Falls, Idaho 83402, telephone

208/523–8000, FAX 208/529–9610.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 50 people.

Background

Under a Memorandum of

Understanding (MOU) signed in

December 1990 with DOE and replaced

by an MOU signed in 1996, the

Department of Health and Human

Services (HHS) was given the

responsibility and resources for

conducting analytic epidemiologic

investigations of residents of

communities in the vicinity of DOE

facilities, workers at DOE facilities, and

other persons potentially exposed to

radiation or to potential hazards from

non-nuclear energy production use.

HHS delegated program responsibility

to CDC.

In addition, an MOU was signed in

October 1990 and renewed in November

1992 between ATSDR and DOE. The

MOU delineates the responsibilities and

procedures for ATSDR’s public health

activities at DOE sites required under

sections 104, 105, 107, and 120 of the

Comprehensive Environmental

Response, Compensation, and Liability

Act (CERCLA or ‘‘Superfund’’). These

activities include health consultations

and public health assessments at DOE

sites listed on, or proposed for, the

Superfund National Priorities List and

at sites that are the subject of petitions

from the public; and other healthrelated activities such as epidemiologic

studies, health surveillance, exposure

and disease registries, health education,

substance-specific applied research,

emergency response, and preparation of

toxicological profiles.

Purpose: This subcommittee is

charged with providing advice and

recommendations to the Director, CDC,

and the Administrator, ATSDR,

regarding community, American Indian

Tribes, and labor concerns pertaining to

CDC’s and ATSDR’s public health

activities and research at this DOE site.

The purpose of this meeting is to

provide a forum for community,

American Indian Tribal, and labor

interaction and serve as a vehicle for

community concern to be expressed as

advice and recommendations to CDC

and ATSDR.

Matters to be Discussed: Agenda items

include presentations from the National

Center for Environmental Health

(NCEH) regarding current activities, the

National Institute for Occupational

Safety and Health and ATSDR will

provide updates on the progress of

current studies, and working group

discussions. On December 11, at 7 p.m.,

the meeting will continue in order to

allow more time for public input and

comment.

Agenda items are subject to change as

priorities dictate.

CONTACT PERSONS FOR MORE

INFORMATION: Arthur J. Robinson, Jr., or

Sharona Woodley, Radiation Studies

Branch, Division of Environmental

Hazards and Health Effects, NCEH, CDC,

4770 Buford Highway, NE, (F–35),

Atlanta, Georgia 30341–3724, telephone

770/488–7040, FAX 770/488–7044.
62062 Federal Register / Vol. 62, No. 224 / Thursday, November 20, 1997 / Notices

Dated: November 13, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–30475 Filed 11–19–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee for EnergyRelated Epidemiologic Research;

Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: Advisory Committee for EnergyRelated Epidemiologic Research.

Times and Dates: 9 a.m.–5 p.m., December

8, 1997; 9 a.m.–12 noon, December 9, 1997.

Place: Hyatt Regency Crystal City, 2799

Jefferson Davis Highway, Arlington, Virginia

22202, telephone 703/418–1234, FAX 703/

418–1289.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 50 people.

Purpose: This committee is charged with

providing advice and recommendations to

the Secretary; the Assistant Secretary for

Health; the Director, CDC; and the

Administrator, Agency for Toxic Substances

and Disease Registry (ATSDR), on

establishment of a research agenda and the

conduct of a research program pertaining to

energy-related analytic epidemiologic

studies.

Matters to be Discussed: Agenda items will

include: presentations from the National

Center for Environmental Health (NCEH), the

National Institute for Occupational Safety

and Health, and ATSDR updates on the

progress of current studies; a discussion of

Work Group recommendations, and public

involvement activities.

Agenda items are subject to change as

priorities dictate.

CONTACT PERSON FOR MORE INFORMATION:

Michael J. Sage, Deputy Chief, Radiation

Studies Branch, Division of

Environmental Hazards and Health

Effects, NCEH, CDC, 4770 Buford

Highway, NE, (F–35), Atlanta, Georgia

30341–3724, telephone 770/488–7040,

FAX 770/488–7044.

Dated: November 13, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–30476 Filed 11–19–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention (CDC)

The National Center for Environmental

Health (NCEH) of the Centers for

Disease Control and Prevention (CDC);

Cancellation of Meeting

This notice announces the

cancellation of a previously announced

meeting: Workshop on Screening and

Tracking Systems for Early Hearing

Detection and Intervention (EHDI).

Federal Register Notice Citation of

Previous Announcement: FR Doc.

17oc97–115. Published October 17,

1997 (Volume 62, Number 200, Page

54116).

Previously Announced Times and

Dates: 8 a.m.–5 p.m. December 11, 1997.

8:30 a.m.–1 p.m. December 12, 1997.

Change in the Meeting: This meeting

has been canceled.

CONTACT PERSON FOR MORE INFORMATION:

June Holstrum, Ph.D., Division of Birth

Defects and Developmental Disabilities,

CDC, NCEH, 4770 Buford Highway, NE,

M/S F–15, Atlanta, Georgia 30341. Email ehdi@cdc.gov, telephone 770/488–

7401, fax 770/488–7361.

Dated: November 13, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–30480 Filed 11–19–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0428]

Amoco Corp.; Filing of Food Additive

Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Amoco Corp. has filed a petition

proposing that the food additive

regulations be amended to include

dimethyl-2,6-naphthalene dicarboxylate

and 2,6-naphthalene dicarboxylic acid

as polybasic acids intended for use as

components of resinous and polymeric

coatings that contact food.

FOR FURTHER INFORMATION CONTACT:

Mark A. Hepp, Center for Food Safety

and Applied Nutrition (HFS–215), Food

and Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3098.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act

(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),

notice is given that a food additive

petition (FAP 7B4555) has been filed by

Amoco Corp., One Prudential Plaza, 130

East Randolph St., Chicago, IL 60601–

6207. The petition proposes to amend

the food additive regulations in

§ 175.300 Resinous and polymeric

coatings (21 CFR 175.300) to include

dimethyl-2,6-naphthalene dicarboxylate

and 2,6-naphthalene dicarboxylic acid

as polybasic acids intended for use as

components of resinous and polymeric

coatings that contact food.

The agency has determined under 21

CFR 25.32(i) and (j) that this action is of

a type that does not individually or

cumulatively have a significant effect on

the human environment. Therefore,

neither an environmental assessment

nor an environmental impact statement

is required.

Dated: October 21, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval,

Center for Food Safety and Applied Nutrition.

[FR Doc. 97–30481 Filed 11–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food And Drug Administration

[Docket No. 97F–0469]

General Electric Co.; Filing of Food

Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that General Electric Co. has filed a

petition proposing that the food additive

regulations be amended to provide for

the expanded safe use of phosphorous

acid, cyclic butylethyl propanediol,

2,4,6-tri-tert-butylphenyl ester, which

may contain up to 1 percent by weight

of triisopropanolamine, as an

antioxidant and/or stabilizer in high

density polyethylene and high density

olefin copolymers intended for use in

contact with food.

FOR FURTHER INFORMATION CONTACT: Vir

D. Anand, Center for Food Safety and

Applied Nutrition (HFS–216), Food and

Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act